Ace Inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB) are among the most common anti-hypertensive (high blood pressure) medications in the world. Early in the Covid-19 outbreak there were concerns about these medications among the critically ill. This is because the SARS-CoV2 virus is believed to infect human lung cells through our ACE-2 receptors. However, the article referenced below indicates that blocking these receptors with ARB drugs, or inhibiting the angiotensin converting enzyme with ACEI drugs, just might help reduce the seriousness of the pulmonary impact of Covid-19, thereby improving survival of Covid-19 lung infections.
This publication is not based on data obtained under ideal research conditions (it is not a randomized double blinded controlled study) but the findings are nevertheless compelling and worthy of the medical community’s consideration
Take a look at our Covid-Page for a volume of fact-checked authoratative information about Covid-19.
Have a peak at our ultra-thin and durable Medication-Cards for the wallet.
Justin Groode MD | Patient Advocate Alliance LLC